BioMarin Pharma Executive Pay Details Revealed
Ticker: BMRN · Form: DEF 14A · Filed: Apr 8, 2025 · CIK: 1048477
| Field | Detail |
|---|---|
| Company | Biomarin Pharmaceutical INC (BMRN) |
| Form Type | DEF 14A |
| Filed Date | Apr 8, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, annual-filing
Related Tickers: BMRN
TL;DR
BioMarin's exec pay filing is out - check out 2024 compensation details for Bienaimé & Hardy.
AI Summary
BioMarin Pharmaceutical Inc. filed its DEF 14A on April 8, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. Key individuals like Jean-Jacques Bienaimé and Alexander Hardy had compensation periods extending through 2023 and 2024, with specific dates like May 20, 2024, and September 30, 2024, noted for certain members. The filing also references equity awards for the applicable year 2024.
Why It Matters
This filing provides transparency into how BioMarin Pharmaceutical compensates its top executives, which can influence investor decisions and employee morale.
Risk Assessment
Risk Level: low — This is a routine annual filing disclosing executive compensation and does not present new or unusual risks.
Key Numbers
- 2024 — Fiscal Year End (Compensation reporting period)
- 20250408 — Filing Date (Date of submission to SEC)
Key Players & Entities
- BIOMARIN PHARMACEUTICAL INC (company) — Filer
- Jean-Jacques Bienaimé (person) — Executive
- Alexander Hardy (person) — Executive
- Cristin Hubbard (person) — Board Member
- Gregory R. Friberg M.D. (person) — Board Member
- 0001048477-25-000045 (filing_id) — Accession Number
FAQ
What is the primary purpose of a DEF 14A filing?
A DEF 14A filing, also known as a Proxy Statement, is used to solicit shareholder votes on important corporate matters, including the election of directors and executive compensation.
Who are the key individuals mentioned in relation to compensation periods?
Jean-Jacques Bienaimé and Alexander Hardy are mentioned with compensation periods extending through 2023 and 2024.
What specific dates are associated with board member roles?
Cristin Hubbard is noted as a Member with a compensation period ending May 20, 2024, and Gregory R. Friberg M.D. is noted as a Member with a compensation period ending September 30, 2024.
What is the company's fiscal year end?
BioMarin Pharmaceutical Inc.'s fiscal year ends on December 31.
What type of awards are referenced in the filing for the 2024 fiscal year?
The filing references equity awards ('EqtyAwrds') for the applicable year 2024, specifically 'EqtyAwrdsInSummryCompstnTblForAplblYrMember' and 'EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember'.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 8, 2025 by Jean-Jacques Bienaimé regarding BIOMARIN PHARMACEUTICAL INC (BMRN).